Objectives: To review our institutional experience and to analyze the clinical decisions made after a cytological diagnosis of atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS). Study Design: This is a retrospective review of all thyroid fine-needle aspiration (FNA) cytologies performed in the Hospital Clínico San Carlos (Madrid) between 2010 and 2014. Results: One hundred thirty thyroid FNA were categorized as AUS/FLUS (5%). One hundred six (81.5%) patients were women, and the mean age was 59 years. In 61 patients a repeated FNA was performed (46%). Fifty-five nodules were treated surgically (42.3%), with a histopathological diagnosis of nodular hyperplasia in 36 cases (65%), adenoma in 11 (20%), and carcinoma in 8 (14.5%). In the group of nonsurgical patients (n = 75), a repeated FNA was performed in 43 (57.3%) cases. We found no statistically significant association between sex or age and clinical management (p = 0.13 and p = 0.31, respectively). Conclusions: Clinical management after an AUS/FLUS FNA diagnosis is erratic and does not match standardized management protocols. The AUS/FLUS classification has not led to new diagnostic tests in a relevant percentage of patients. The implementation of consensual institutional strategies could lead to better management of these cases.

Keywords:
Atypia of undetermined significance, Follicular lesion of undetermined significance, Clinical management, Bethesda system
1.
Hegedüs L: Clinical practice: the thyroid nodule. N Engl J Med 2004;351:1764-1771.
2.
Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, et al: Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology 2005;237:794-800.
3.
Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedüs L, et al: AACE/AME/ETA thyroid nodule guidelines. Endocr Pract 2010;16(suppl 1):3.
4.
Wu HH, Jones JN, Osman J: Fine-needle aspiration cytology of the thyroid: ten year experience in a community teaching hospital. Diagn Cytopathol 2006;34:93-96.
5.
Ali SZ, Cibas ES: The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria and Explanatory Notes. New York, Springer, 2010.
6.
Layfield LJ, Cibas ES, Baloch Z: Thyroid fine needle aspiration cytology: a review of the National Cancer Institute state of the science symposium. Cytopathology 2010;21:75-85.
7.
VanderLaan PA, Marqusee E, Krane JF: Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated FNA be the preferred initial approach? Am J Clin Pathol 2011;135:770-775.
8.
Krane JK, Vanderlaan PA, Faquin WC, Renshaw AA: The atypia of undetermined significance/follicular lesion of undetermined significance malignant ratio: a proposed performance measure for reporting in the Bethesda system for thyroid cytopathology. Cancer Cytopathol 2012;120:111-116.
9.
Dincer N, Balci S, Yazgan A, Guney G Ersoy R, Cakir B, et al: Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine-needle aspiration cytology. Cytopathology 2013;24:385-390.
10.
Chaves S, Fernandez-Aceñero MJ, Cazorla A, Cedeño M, Fortes J, Gavín E, et al: Implementation of a joint protocol for the management of thyroid nodules with a cytological diagnosis of follicular lesion of undetermined significance: experience in one hospital. Cytopathology 2013;24:81-84.
11.
Faquin WC, Baloch ZW: Fine-needle aspiration of follicular patterned lesions of the thyroid: diagnosis, management, and follow-up according to National Cancer Institute (NCI) recommendations. Diagn Cytopathol 2010;38:731-739.
12.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al: 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133.
13.
Rabaglia JL, Kabbani W, Wallace L, Holt S, Watumull L, Pruitt J, et al: Effect of the Bethesda system for reporting thyroid cytopathology on thyroidectomy rates and malignancy risk in cytologically indeterminate lesions. Surgery 2010;148:1267-1272, discussion 1272-1273.
14.
Walts AF, Bose S, Fan X, Frishberg D, Scharre K, de Peralta-Venturina M, et al: A simplified Bethesda system for reporting thyroid cytopathology using only four categories improves intra- and inter observer diagnostic agreement and provides non-overlapping estimates of malignancy risks. Diagn Cytopathol 2012;40(suppl 1):E62-E68.
15.
Cibas ES, Baloch ZW, Fellegara G, LiVolsi VA, Raab SS, Rosai J, et al: A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Ann Intern Med 2013;159:325-332.
16.
Iskandar ME, Bonomo G, Avadhani V, Persky M, Lucido D, Wang B, et al: Evidence for overestimation of the prevalence of malignancy in indeterminate thyroid nodules classified as Bethesda category III. Surgery 2015;157:510-517.
17.
Nagarkatti SS, FaquinWc, Lubitz CC, García DM, Barbesino G, Ross DS, et al: Management of thyroid nodules with atypical cytology on fine-needle aspiration biopsy. Ann Surg Oncol 2013;20:60-65.
18.
Ho AS, Sarti EE, Jain KS, Wang H, Nixon IJ, Shaha AR, et al: Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid 2014;24:832-839.
19.
Chen JC, Pace SC, Chen BA, Khiyami A, McHenry CR: Yield of repeat fine-needle aspiration biopsy and rate of malignancy in patients with atypia or follicular lesion of undetermined significance: the impact of the Bethesda system for reporting thyroid cytopathology. Surgery 2012;152:1037-1044.
20.
Layfield LJ, Morton MJ, Cramer HM, Hirschowitz S: Implications of the proposed thyroid fine-needle aspiration category of ‘‘follicular lesion of undetermined significance'': a five-year multi-institutional analysis. Diagn Cytopathol 2009;37:710-714.
21.
Broome JT, Cate F, Solorzano CC: Utilization and impact of repeat biopsy for follicular lesion/atypia of undetermined significance. World J Surg 2014;38:628-633.
22.
Jo VY, Stelow EB, Dustin SM, Hanley KZ: Malignancy risk for fine needle aspiration of thyroid lesions according to the Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol 2010;134:450-456.
23.
Nayar R, Ivanovich M: The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer 2009;117:195-202.
24.
McElroy MK, Mahooti S, Hasteh F: A single institution experience with the new Bethesda system for reporting thyroid cytopathology correlation with existing cytologic, clinical, and histological data. Diagn Cytopathol 2014;42:564-569.
25.
Sullivan PS, Hirschowitz SL, Fung PC, Apple SK: The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda system. Cancer Cytopathol 2014;122:866-872.
26.
Ryu YJ, Jung YS, Yoon HC, Hwang MJ, Shin SH, Cho JS, et al: Atypia of undetermined significance on thyroid fine needle aspiration: surgical outcome and risk factors for malignancy. Ann Surg Treat Res 2014;86:109-114.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.